Introduction
Microtia, a congenital anomaly of the auricle with a wide spectrum of presentation with challenging reconstruction. Management depends on its severity with variable reconstructive options. Preoperative planning is crucial to achieve better results and decrease operative time. In this article, we aim to show the utility of an affordable technology with the use of a smartphone, an open-source computer-aided design (CAD) software, and a desktop 3D printer in planning future ear location for unilateral microtia reconstruction in step-by-step fashion.
Methodology
Facial 3D scanning was done using a smartphone that has a three-dimensional capture system. The scan was then used in an open-sourced CAD software. A mirror image mask was created by reflecting normal side anatomic features to the abnormal side. The mask constitutes the desired area for reconstruction given the ear anthropometrics. Finally, the model was 3D printed and fitted to the patient in which incision marking and framework location was planned.
Discussion
Ear reconstruction requires careful assessment and specific technicality in its anthropometric measures. One important aspect in surgical planning resides in future ear location that varies between person to person. This variability makes the reconstructive option more customized based on the patient's needs. The utility of CAD software in the measurement and planning can help predict and optimize postoperative results as possible; however, it has major technical demands and added surgical fees.
Conclusion
Herein, we demonstrate the efficacy of an easy-to-use system beneficial for preoperative planning that is affordable, time-saving, and cost effective.
Background: Alemtuzumab is a humanized anti-CD 52 monoclonal antibody approved as a disease-modifying therapy for active relapsing-remitting Multiple Sclerosis (MS). Alemtuzumab has been associated with several adverse effects, including infusion-associated reactions, infections, acquired autoimmune diseases, and malignancies. Case presentation: We report a case of Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy and stroke in a 52-year-old man that occurred 8 months after initiation of alemtuzumab. The laboratory testing was consistent with autoimmune haemolytic anaemia. Computed tomography of the chest and bronchoscopy revealed an alveolar haemorrhage. Stroke workup revealed acute infarcts in bilateral occipital territories. Conclusion: This is the first case report of a simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and ischaemic stroke after the first alemtuzumab course in relapsing-remitting MS patient. This case highlights the potential for the co-occurrence of unexpected and potentially life-threatening complications of alemtuzumab therapy necessitating rigorous monitoring once prescribed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.